Actively Recruiting
Evaluating Dapirolizumab Pegol Compared to Placebo as Add-On Treatment for Moderate to Severe Systemic Lupus Erythematosus in a Multicenter Randomized Trial
Led by UCB Biopharma SRL · Updated on 2026-11-02
450
Participants Needed
245
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Research Team
U
UCB Cares
U
UCB Cares
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here